Source: Eur Respir Rev 2013; 22: 414-416



Rating:

Share or cite this content

Citations should be made in the following way:
Jakob Lager, Ole Hilberg, Anders Løkke, Elisabeth Bendstrup. Severe interstitial lung disease following treatment with certolizumab pegol: a case report},. Eur Respir Rev 2013; 22: 414-416

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Anti-interleukin-5 therapy in severe asthma}, Source: Eur Respir Rev 2013; 22: 251-257 Year: 2013 Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis Source: Eur Respir J 2014; 44: 1296-1307 Year: 2014 Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Short term glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: "REDUCE*", a non-inferiority multicenter trial. (*Reduction in the Use of Corticosteroids in Exacerbated COPD; ISRCTN19646069) Source: Annual Congress 2012 - Acute exacerbation in COPD Year: 2012 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Gemcitabine induced pulmonary toxicity in a single patient: case report Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Anti-interleukin 5 treatment in moderate to severe eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 Severe refractory asthma: an update}, Source: Eur Respir Rev 2013; 22: 227-235 Year: 2013 Emphysematous lung sealant (ELS) therapy reduces CRP, an index of inflammation, in patients with severe emphysema (clinicaltrials.gov #NCT NCT00884962) Source: Annual Congress 2013 –Bronchoscopic treatment of COPD and asthma: where are we going? Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021